Alembic Pharmaceuticals has reported results for fourth quarter and year ended March 31, 2021.
The company has reported a fall of 26.47% in its net profit at Rs 231.11 crore for the quarter under review as compared to Rs 314.30 crore for the same quarter in the previous year. Total income of the company decreased by 1.55% at Rs 1161.27 crore for Q4FY21 as compared Rs 1179.57 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a rise of 11.61% in its net profit after taxes, non-controlling interests and share of profit of Associates and Joint Ventures at Rs 250.70 crore for the quarter under review as compared to Rs 224.63 crore for the same quarter in the previous year. Total income of the company increased by 6.34% at Rs 1284.34 crore for Q4FY21 as compared Rs 1207.72 crore for the corresponding quarter previous year.
For the year ended March 31, 2021, the company has reported a rise of 21.25% in its net profit at Rs 1175.39 crore as compared to Rs 969.40 crore for the previous year. Total income of the company increased by 18.60% at Rs 5061.18 crore for year under review as compared to Rs 4267.31 crore for year ended March 31, 2020.
For the year ended March 31, 2021, on the consolidated basis, the company has reported a rise of 42.14% in its net profit after taxes, non-controlling interests and share of profit of Associates and Joint Ventures at Rs 1178.11 crore as compared to Rs 828.82 crore for the previous year. Total income of the company increased by 17.19% at Rs 5403.14 crore for year under review as compared to Rs 4610.69 crore for year ended March 31, 2020.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1504.25 |
Dr. Reddys Lab | 6263.70 |
Cipla | 1406.25 |
Zydus Lifesciences | 948.20 |
Lupin | 1615.85 |
View more.. |